FDA loses power to demand drug-safety tests for cheaper biologics

What it does

This bill modifies FDA requirements for approving biosimilar drugs (cheaper copies of expensive biologic medicines) by making clinical testing more flexible. Instead of requiring manufacturers to always conduct expensive comparative studies proving their biosimilar works identically to the original drug, the FDA can now skip those studies in many cases—but only if the FDA provides written justification upfront. The bill also streamlines the review process by requiring the FDA to issue written determinations about what testing is needed within 60 days of application, and prevents the FDA from adding new testing requirements after that deadline without sponsor agreement or detailed scientific justification.

Why we flagged it

The bill's core mechanism is procedural and substantive reform of FDA biosimilar licensing standards, making approval faster and less testing-intensive while adding procedural safeguards (written justifications, 60-day deadlines). It is not a tax measure, appropriation, or commemorative act.

What the text implies

• Biosimilar manufacturers may face less rigorous comparative efficacy testing, potentially allowing products to market with weaker clinical evidence of equivalence to reference drugs—a trade-off between speed/cost and safety certainty.
• The 60-day deadline for FDA written determinations may create pressure on FDA staff to make determinations quickly or lose the ability to require additional studies, potentially favoring applicants over thorough review.

The full analysis lists 4 implications of this text.

Who stands to gain

biosimilar manufacturers; generic/biosimilar drug companies; health insurers and pharmacy benefit managers (via lower drug costs)